Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans
Sign Up to like & getrecommendations! Published in 2023 at "Xenobiotica"
DOI: 10.1080/00498254.2023.2176267
Abstract: Abstract SHR0302, a selective JAK1 inhibitor developed by Jiangsu Hengrui Pharmaceutical Co., was intended for the treatment of rheumatoid arthritis. In this study, we evaluated the pharmacokinetics, mass balance, and metabolism of SHR0302 in six… read more here.
Keywords: 14c shr0302; mass balance; jak1 inhibitor; shr0302 selective ... See more keywords
AB0095 PRECLINICAL CHARACTERIZATION OF CJ-15314, A HIGHLY SELECTIVE JAK1 INHIBITOR, FOR THE TREATMENT OF AUTOIMMUNE DISEASES
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.650
Abstract: Background: Janus kinases (JAK1, JAK2, JAK3, and TYK2) play critical roles in mediating various cytokine signaling, and has been developed as a target for autoimmune diseases such as RA. Tofacitinib, oral Pan-JAK inhibitor, demonstrated efficacy… read more here.
Keywords: jak1; jak1 inhibitor; employee healthcare;
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
Sign Up to like & getrecommendations! Published in 2017 at "Internal Medicine"
DOI: 10.2169/internalmedicine.56.7871
Abstract: Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F,… read more here.
Keywords: jak1 inhibitor; polycythemia vera; exon mutations; myelofibrosis ... See more keywords
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.
Sign Up to like & getrecommendations! Published in 2018 at "Future oncology"
DOI: 10.2217/fon-2017-0298
Abstract: Ruxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide. Studies have demonstrated that Rux improves disease-related symptoms and splenomegaly. A late emerging observation… read more here.
Keywords: jak1 inhibitor; inhibitor ruxolitinib; review jak1; updated review ... See more keywords